Table 6:
Comparison between baseline data and 6 and 12 months post-SGLT2i treatment.
| Characteristics | Baseline | 6 months post-SGLT2i | 12 months post-SGLT2i | P-value* |
|---|---|---|---|---|
| Body weight (kg), mean (SD) (n = 194) | 83.9 (17.6) | 81.8 (17.2) | 80.6 (17.4) | <.001a,b,c |
| SBP (mmHg), mean (SD) (n = 198) | 137.2 (15.7) | 133.0 (15.9) | 132.0 (14.9) | <.001a,b |
| DBP (mmHg), mean (SD) (n = 198) | 76.7 (9.8) | 74.2 (9.8) | 74.5 (10.0) | <.001a,b |
| Haemoglobin (g/dl), mean (SD) (n = 218) | 13.6 (1.7) | 14.1 (1.6) | 14.2 (1.5) | <.001a,b |
| Fasting glycaemia (mg/dl), mean (SD) (n = 224) | 152.8 (42.2) | 135.2 (37.2) | 139.1 (50.0) | <.001a,b |
| HbA1c (%), mean (SD) (n = 188) | 7.61 (1.18) | 7.12 (0.94) | 7.14 (0.99) | <.001a,b |
| eGFR (ml/min/1.73 m2), mean (SD) (n = 225) | 60.2 (20.2) | 58.5 (20.9) | 58.8 (21.2) | .01a |
| Uric acid (mg/dl), mean (SD) (n = 188) | 6.20 (1.41) | 5.79 (1.30) | 5.70 (1.26) | <.001a,b |
| Magnesium (mg/dl), mean (SD) (n = 138) | 1.61 (0.27) | 1.76 (0.25) | 1.79 (0.27) | <.001a,b |
| UPCR (mg/g), median (IQR) (n = 152) | 156 (80–380) | 156 (90–370) | 150 (90–407) | .320 |
| Baseline UPCR <300 mg/g, median (IQR) (n = 132) | 156 (80–380) | 159 (90–370) | 150 (90–407) | .119 |
| Baseline UPCR ≥300 mg/g, median (IQR) (n = 49) | 750 (390–1410) | 520 (270–950) | 440 (230–700) | .001a,b |
| UACR (mg/g), median (IQR) (n = 62) | 82 (28–253) | 50 (18–210) | 50 (17–180) | <.001a,b |
| FENa (%), median (IQR) (n = 78) | 1.07 (0.76–1.63) | 1.34 (0.93–1.82) | 1.29 (0.92–1.96) | .002a,b |
| Glycosuria (mg/dl), median (IQR) (n = 201) | 0 (0–150) | 1000 (500–1000) | 1000 (500–1000) | <.001a,b |
| Tacrolimus dose (mg/kg/day), mean (95% CI) (n = 167) | 0.0394 (0.0282) | 0.0389 (0.0266) | 0.0388 (0.0279) | |
| Tacrolimus level (ng/ml), mean (SD) (n = 192) | 6.92 (2.00) | 6.86 (2.00) | 7.14 (2.10) | .717 |
| Mycophenolic acid dose (mg/day), mean (SD) (n = 177) | 856 (298) | 854 (288) | 846 (292) | .822 |
| Prednisone treatment, n (%) (n = 224) | 111 (55) | 105 (52.0) | 104 (51.5) | .092 |
| Prednisone dose (mg/day), mean (SD) (n = 186) | 4.73 (1.81) | 4.67 (1.78) | 4.64 (1.78) | .430 |
| Antidiabetic drugs, n (%) | ||||
| Insulin (n = 224) | 118 (52.7) | 110 (49.1) | 105 (46.9) | .009b |
| Long-acting insulin (n = 224) | 117 (52.2) | 108 (48)2) | 105 (46.9) | .026b |
| Short-acting insulin (n = 224) | 65 (29.0) | 59 (26.3) | 57 (25.5) | .100 |
| Metformin (n = 224) | 74 (33.0) | 88 (39.3) | 92 (41.8) | <.002a,b |
| DPP-4i ( n = 221) | 89 (40.3) | 86 (38.9) | 83 (37.6) | .528 |
| GLP-1 RA (n = 221) | 26 (11.8) | 29 (13.1) | 34 (15.4) | .255 |
SBP, systolic blood pressure; DBP, diastolic blood pressure; FENa, fractional excretion of sodium; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, glucagon-like peptide 1 receptor agonist.
*
Manova test; Bonferroni post hoc analysis.
a
P < .05 baseline versus 6 months post-SGLT2i.
b
P < .05 basal versus 12 months post-SGLT2i.
c
P < .05 6 versus 12 months post-SGLT2i.